Metabolic Syndrome (Cardiovascular Aspects)

Metabolic Syndrome (Cardiovascular Aspects)

Five measurements define metabolic syndrome, and three abnormal values among them are sufficient for the label: waist circumference above 40 inches in men or 35 in women, fasting glucose above 100 mg/dL, triglycerides above 150 mg/dL, HDL cholesterol below 40 in men or 50 in women, and blood pressure above 130/85. About 34 percent of US adults meet those criteria, a proportion that has risen in parallel with the obesity that drives it.

The clustering is not coincidental. Visceral adipose tissue is metabolically distinct from subcutaneous fat: it drains into the portal circulation, delivering free fatty acids directly to the liver, where they promote gluconeogenesis and very-low-density lipoprotein production. That single anatomical fact links three of the five criteria at once, raising glucose and triglycerides while lowering HDL. Insulin resistance completes the pattern, and elevated insulin promotes renal sodium retention and sympathetic activity, which connects the cluster to the fifth criterion.

Whether the syndrome constitutes a discrete entity or is best read as a convenient summary of correlated risks has been debated since the definition was introduced. From the cardiovascular perspective the practical answer is that the components are each independently associated with risk and that their coexistence is common enough to justify looking for the others once one is found.

One ingredient is graded against the cardiovascular aspects of this endpoint here: berberine, at Grade B on 20 studies and 2,500 participants. Its mechanistic case is the most developed of any plant alkaloid in this collection. Berberine activates AMP-activated protein kinase, the cellular energy sensor that also mediates part of metformin's action, and it upregulates hepatic LDL-receptor expression through a route independent of the statins. It therefore has a plausible relationship with several of the five criteria at once rather than with only one, which is unusual.

Much of the recent work remains preclinical and mechanistic. Rodent studies have examined berberine in combination with evodiamine against diet-induced hepatic steatosis, reporting changes in gut microbial composition alongside the metabolic readouts ^[1], and further animal work has attributed part of its effect on steatohepatitis to enrichment of Akkermansia muciniphila in the gut ^[2]. That line of research is interesting because berberine is poorly absorbed, which makes an action mediated by the intestinal microbiota more plausible than one requiring high systemic concentrations. It is also a reminder of the distance between a rodent model and a clinical endpoint.

The dominant determinant remains visceral adiposity, with insulin resistance, sedentary living, a diet high in refined carbohydrate and saturated fat, genetics, ageing and sleep apnea listed alongside it. Each of the five defining measurements responds to changes in that set, and the evidence supporting them is larger than the evidence behind any single ingredient.